DDNews

DDNews is a monthly publication focused on the latest developments in technology and business within the pharmaceutical and biotechnology sectors. While many in the industry, including friends and competitors, offered their best wishes, we could sense their skepticism: "Good luck with that!" The market for drug discovery publications was quite competitive. However, as time passed, numerous other publications either merged, shut down, or reduced their offerings, while DDNews remained committed to enhancing our services for our readers.

International, National, Trade/B2B

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#740429

United States

#469973

Health/Biotechnology and Pharmaceuticals

#441

Traffic sources

Monthly visitors

Articles

Which clinical developments are cancer experts watching closely?

4 days ago | drugdiscoverynews.com | Stephanie DeMarco

At the recent American Association for Cancer Research meeting (AACR 2025), we asked cancer researchers working in biotech, pharma, and academia which cancer clinical trials or developments they’re keeping track of. Which cancer clinical developments are you watching closely? Because we're interested in colorectal cancer, specifically microsatellite stable colorectal cancer, we're really curious to see what cytotoxic T-lymphocyte associated antigen 4 (CTLA-4) inhibition will do.
How turmoil at the NIH is affecting cancer research

1 week ago | drugdiscoverynews.com | Stephanie DeMarco

As more than 20,000 researchers, clinicians, patients, and students from all over the world descended on Chicago for the American Association of Cancer Research (AACR)’s 2025 Annual Meeting, the recent upheaval at the National Institutes of Health (NIH) never seemed far from people’s minds. Over the past few months, delays or outright cancellations of NIH grants and firing of NIH staff have halted critical research.
How integrated droplet-based systems are accelerating therapeutic development

2 weeks ago | drugdiscoverynews.com | Bree Coven Foster

As microfluidics continue to gain ground as a critical enabler of single-cell research and therapeutic development, companies at the forefront of the field are evolving to meet growing demand for scalable, integrated solutions.
The biggest barriers in drug development today

2 weeks ago | drugdiscoverynews.com | Allison Whitten

We asked industry leaders and academic researchers in the fields of hematology, pain, HIV, and neurology what they see as the major obstacles holding back the development of new drugs today. What do you see as the biggest barriers in drug development today?
Editing precious patient cells in a single drop

3 weeks ago | drugdiscoverynews.com | Stephanie DeMarco

Genetic screens can give researchers all sorts of insights into how a particular small molecule or drug candidate might act in a given disease. While these kinds of screens work well when scientists are working with a cell type that they can easily culture and expand, their task becomes much harder if they want to perform the same experiments in rare patient cells or cells that are more difficult to culture.
What makes synthetic DNA the better choice for gene therapy development?

4 weeks ago | drugdiscoverynews.com | Bree Coven Foster

Synthetic DNA is increasingly used for gene therapies due to its fast production and improved scalability compared to traditional plasmid-based methods. Credit: iStock.com/ktsimageSynthetic DNA is increasingly used for gene therapies due to its fast production and improved scalability compared to traditional plasmid-based methods.
Giving promising drug compounds a second chance

1 month ago | drugdiscoverynews.com | Allison Whitten

After two decades working in leadership positions at big pharmaceutical companies like AstraZeneca and Novartis, immunologist and emergency physician Volkan Manga wanted to go in a new direction. He realized that as he watched some drugs pass through clinical trials and reach real patients, many more drugs with great potential sat by the wayside.
Solving the fill/finish bottleneck in clinical drug development

1 month ago | drugdiscoverynews.com | Bree Coven Foster

In the world of drug development, securing timely access to fill/finish services can often pose a critical bottleneck, especially for clinical trials requiring small-volume production. Fill/finish refers to the final steps in the production of injectable pharmaceutical drug substances, including the process of filling vials with a drug substance, sealing them, and ensuring they are sterile and ready for use in clinical settings.
A new approach to treating Duchenne muscular dystrophy

1 month ago | drugdiscoverynews.com | Bree Coven Foster

Duchenne muscular dystrophy (DMD) has long been understood as a disease driven by the absence of dystrophin, a protein essential for maintaining muscle integrity. Most therapeutic efforts have focused on restoring dystrophin through gene therapy, exon-skipping, or other genetic approaches. However, emerging research suggests that dystrophin’s role extends beyond structural support — it also plays a critical part in regulating muscle regeneration.
How high-throughput flow cytometry is transforming drug discovery

1 month ago | drugdiscoverynews.com | Bree Coven Foster

From understanding immune responses to screening new drug candidates, flow cytometry plays a critical role in modern biomedical research. By rapidly analyzing thousands of cells per second, researchers can gather precise, multiparametric data at the single-cell level. Recent innovations in automation and high-throughput screening have further expanded the technology’s potential, making it a powerful tool for drug discovery.